title: Retrospective comparison of mechanical percutaneous thrombectomy of hemodialysis arteriovenous grafts with the Arrow-Trerotola device and the lyse and wait technique.
abstract: OBJECTIVE
  The purpose of our study was to determine whether pharmacologic thrombolysis with urokinase in the lyse and wait (L&W) technique compared with mechanical declotting using the Arrow-Trerotola percutaneous thrombectomy device is more efficient, safer, or less expensive in treating thrombosed hemodialysis grafts.
  
  
  METHODS
  The files of 157 patients who underwent arteriovenous graft declotting from 2000 to 2007 at one tertiary care center were reviewed. The study group included 83 women and 74 men with a mean age of 68 +/- 12 years (range, 27-95 years). A total of 563 procedures were performed: 427 with the L&W technique and 136 with mechanical percutaneous thrombectomy using the percutaneous thrombectomy device. The two types of procedures were compared for success rate, complications, average patency time, and cost.
  
  
  RESULTS
  There were no statistically significant differences between the pharmacologic and mechanical procedures in immediate success rate (99% and 98%, respectively) or average patency time (5.44 months and 5.40 months, respectively). The L&W technique was considerably less expensive.
  
  
  CONCLUSIONS
  Given its lower cost and equal efficacy and safety, L&W appears to be preferable to mechanical thrombolysis with a percutaneous thrombectomy device for initial arteriovenous hemodialysis graft declotting.
authors.affiliation: Department of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
authors.forename: Natalia
authors.initials: N
authors.lastname: Vashchenko
authors.forename: Asher
authors.initials: A
authors.lastname: Korzets
authors.forename: Chaim
authors.initials: C
authors.lastname: Neiman
authors.forename: Gil N
authors.initials: GN
authors.lastname: Bachar
authors.forename: Yaacov
authors.initials: Y
authors.lastname: Ori
authors.forename: Alexander
authors.initials: A
authors.lastname: Belenky
authors.forename: Eli
authors.initials: E
authors.lastname: Atar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001166:Arteriovenous Shunt, Surgical; D005260:Female; D006083:Graft Occlusion, Vascular / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage*; D006435:Renal Dialysis; D012189:Retrospective Studies; D017131:Thrombectomy / Q000295:instrumentation*; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*; D014654:Vascular Patency
chemical_list: D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator